Aderamastat (FP-025) is an oral, selective, non-hydroxamate-based, non-competitive inhibitor of matrix metalloproteinase-12 (MMP-12).In 2026, the product was licensed to Primevera Therapeutics from Foresee Pharmaceuticals, granting exclusive global rights.
For research use only. We do not sell to patients.
| Name | Aderamastat ( Synonyms: FP-025 ) |
|---|---|
| Iupac Chemical Name | 5-[3-[4-(3-Methylbenzyloxy)phenylsulfanyl]furan-2-yl]imidazolidine-2,4-dione |
| Synonyms | Aderamastat; FP-025; FP025; FP 025 |
| Molecular Formula | C21 H18 N2 O4 S |
| Molecular Weight | 394.4 |
| Smile | O=C1NC(C(C2=C(SC3=CC=C(OCC4=CC=CC(C)=C4)C=C3)C=CO2)N1)=O |
| InChiKey | CXEKSVVDMIAMLF-UHFFFAOYSA-N |
| InChi | InChI=1S/C21H18N2O4S/c1-13-3-2-4-14(11-13)12-27-15-5-7-16(8-6-15)28-17-9-10-26-19(17)18-20(24)23-21(25)22-18/h2-11,18H,12H2,1H3,(H2,22,23,24,25) |
| CAS Number | 877176-23-3 |
| Related CAS | 877176-23-3 |
| Packaging | Price | Availability | Purity | Shipping Time |
|---|---|---|---|---|
| Bulk | Enquiry | Enquiry | Enquiry |
| Formulation | Solid powder |
|---|---|
| Purity | 98% Min. |
| Storage | Dry, dark and at 0 - 4℃ for short term (days to weeks) or -20℃ for long term (months to years). |
| Solubility | Soluble in DMSO (DMSO : ≥ 100 mg/mL) |
| Handling | Refer to MSDS |
| Shipping Condition | Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs. |
| HS Code | 2934200090 |
| Targets | |
|---|---|
| Mechanism | |
| Cell study | |
| Animal study | |
| Clinical study |